Storage
Keep refrigerated at 2°C to 8°C, protected from direct light and excessive heat.
Do not freeze. If the solution has been frozen, exposed to unsuitable conditions or shows visible changes, it should not be used for research procedures.
Benefits
Each Glyca® Tirzepatide vial contains 0.5 ml of sterile solution, providing 15 mg of Tirzepatide. A dual GIP and GLP-1 receptor agonist.
Administered once weekly. Start with the lowest dose to minimize gastrointestinal effects and increase progressively in 2.5 mg increments under professional guidance.
⚠ Do not exceed 15 mg in any 7-day period.
General information regarding handling, reported adverse effects and the scientific-research context of Tirzepatide.
Keep refrigerated at 2°C to 8°C, protected from direct light and excessive heat.
Do not freeze. If the solution has been frozen, exposed to unsuitable conditions or shows visible changes, it should not be used for research procedures.
In clinical use of Tirzepatide, commonly reported adverse effects include nausea, vomiting, diarrhea, constipation, abdominal discomfort and reduced appetite.
More serious adverse events have also been reported. This information is educational and does not replace evaluation by a qualified healthcare professional.
This content is provided exclusively for scientific and informational purposes. No sale of this medication is conducted through this website. The information presented here is not a prescription, medical advice or an invitation to purchase or use Tirzepatide.